Associated Papers
BRAF mutations and the association of V600E with CD133 and CDX2 expression in a Pakistani colorectal carcinoma cohort.
Hassan S et al.
Bmc Cancer, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
32958805 (PubMed )
Supplement: 41598_2020_72404_MOESM2_ESM.xlsx › ClinVar
Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations.
Fatnassi-Mersni G et al.
Journal of Cutaneous Pathology, 2020
TGPred: a tumor gene prediction webserver for analyzing structural and functional impacts of variants.
Liu J et al.
Journal of Molecular Cell Biology, 2020
32246141 (PubMed )
Supplement: supplementary_material_mjaa007.pdf
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
31795195 (PubMed )
Supplement: cancers-11-01895-s001.zip › ICC_ctDNA_Cancers_Supplementary_Table_5._50_cancer_gene_panel_information.xlsx › cms_106003
Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers.
Gopal P et al.
Nature Communications, 2019
31723142 (PubMed )
Supplement: 41467_2019_13161_MOESM5_ESM.xlsx › Primers_or_Source_Vectors_
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
30064409 (PubMed )
Supplement: 12894_2018_380_MOESM1_ESM.xlsx › Supplementary_Table_1
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
29161613 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_1
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
Ma W et al.
Molecular Diagnosis & Therapy, 2017
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
26527317 (PubMed )
Supplement: oncotarget-06-43731-s002.xlsx › Table_S1
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
26009992 (PubMed )
Supplement: oncotarget-06-24499-s002.xlsx › Supplementary_Table_1
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S et al.
Plos One, 2014
25372287 (PubMed )
Supplement: pone.0111693.s003.xls › ion_ampliseq_cancer_panel_mutat
Development and validation of a clinical trial patient stratification assay that interrogates 27 mutation sites in MAPK pathway genes.
Chang KC et al.
Plos One, 2013
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Deshpande V et al.
Bmc Cancer, 2011
21303542 (PubMed )
Supplement: 1471-2407-11-60-S1.XLS › Table_1_OM3_core_sites
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
21998754 (PubMed )
Supplement: pone.0026071.s009.doc
Profiling critical cancer gene mutations in clinical tumor samples.
MacConaill LE et al.
Plos One, 2009
19924296 (PubMed )
Supplement: pone.0007887.s002.xls › Table_S1_
Select a paper to view details